Symmetry Technologies Inc. licenses a Human Rejuvenation Nutraceutical product from an FDA compliant laboratory. It will sell...
August 01 2013 - 4:00PM
Symmetry Technologies Inc. (OTC:SMMR) is pleased to announce that
it has licensed a Human Rejuvenation Nutraceutical product for
retail sale from a US based FDA compliant laboratory that it will
sell under the brand name "Resurgencell".
"Resurgencell" is Symmetry's initial entrant into the colossal
Nutraceutical market which by the year 2015 is estimated have an
estimated yearly global sales in excess of $200 Billion USD per
year. The Company has received its first shipment of the
"Resurgencell" product and is in the beginning stages of developing
a website in order to sell the product. Symmetry Technologies Inc.
has been exploring various avenues for a substantial online
presence that will help promote the company and its products as
well as direct customers and potential customers to the company
online.
"We are focusing on an internet website to be live and active
within the next 2-3 months. One that will not only promote the
growth of the company and establish our brand but one that will
also provide a potential revenue stream with online purchases,"
says President Chad Reed. "We are obviously excited about the
possibilities of having an online presence that we can build upon.
In conjunction with our retail launch, this could be a huge factor
in future sales of our product"
About The Company:
The Company is in the business of creating, licensing and
marketing nutraceutical products and is developing a proprietary
human rejuvenation nutriceutical with the help of a small group of
PhD molecular biologists. Symmetry believes that by isolating
certain compounds, the effects will be inducement of apoptosis in
senescent cells, stimulation of stem cell growth, and the
suppression of herpes activity. The Company believes that by
clearing tissues with short average telomere length and stimulating
longer telomere cell growth, including differentiation from stem
cell populations, while ameliorating the effects of HSV activity,
they will produce an effect that is tantamount to cell
rejuvenation. The Company is accomplishing these biological tasks
using compounds that have been accepted as safe for human
consumption and already approved by the FDA (Food and Drug
Administration) for human use. Industry trends have shown that
valid opportunities exist in the internet sales of nutraceuticals,
This is based on the Company's belief that with effective
marketing, astronomical opportunities will continue to exist in
internet sales of both pharmaceutical and nutraceutical products,
and that this multibillion dollar industry will continue to shift
towards the majority of its sales being executed online. Additional
information on the Company can be found at www.symmetrytech.net
Safe Harbor Statement:
This press release may contain forward-looking statements,
within the meaning of Section 27 A of the 'Securities Act of 1933
and Sections 21E of the Securities Exchange Act of 1934, and are
subject to the safe harbor created by these sections. Any
statements that express or involve discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives,
goals, assumptions or future events or performance are not
statements of historical fact and may be "forward looking
statements." Forward looking statements are based on expectations,
estimates and projections at the time the statements are made that
involve a number of risks and uncertainties which could cause
actual results or events to differ materially from those presently
anticipated. These forward-looking statements are only made as of
the date of the press release and Symmetry Technologies Inc. does
not undertake any obligation to publicly update such
forward-looking statements to reflect subsequent events or
circumstances.
CONTACT: Chad Reed- President
office@symmetrytech.net
Symmetry Technologies (CE) (USOTC:SMMR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Symmetry Technologies (CE) (USOTC:SMMR)
Historical Stock Chart
From Sep 2023 to Sep 2024